Winners will be announced across the following categories
Bringing innovation to market means navigating complex and often fragmented regulatory pathways. This panel explores the regulatory hurdles that shape timelines, costs, and strategic choices, highlighting the global differences that influence market access. Panellists will also consider whether greater harmonisation across regions is possible, or even desirable, and what that could mean for innovators.
A sneak peek into cutting‑edge research and innovations driving next‑generation biopharma — from human health breakthroughs to translational applications in animal health. Explore novel compounds, delivery technologies and cross‑species strategies accelerating Animal Health
The past 12 months have seen rapid innovation and transformation across the Animal Health industry. Stonehaven Cozmix Group explores advancements in technology and business models shaping the sector’s future, including
Matthias Hofer is the Managing Partner at Stonehaven Consulting AG with over 15 years of experience in Animal Health. He served on the executive committees of two major Animal Health companies for a total of 7 years. Between 2009 and 2013 he led the global Aqua Health business at Novartis Animal Health (NAH). Later on, he was Global Leader Emerging Business at Elanco and a member of Elanco’s global executive committee. During 2014 and with Elanco’s intention to buy NAH, Matthias served as overall pre-merger integration leader on the Novartis side. In that role, Matthias led a large team and efforts to prepare integration pre-closing overall including carve-out preparations of operations linked to Novartis.
